Intensity Therapeutics, Inc. develops intratumoral cancer therapies using proprietary non-covalent drug-conjugation technology. Its lead investigational product candidate, INT230-6, is designed for direct injection into tumors and combines cisplatin, vinblastine sulfate, and the SHAO diffusion and cell-penetration enhancer to disperse cytotoxic agents within cancer cells.
Recurring company news covers INT230-6 clinical development, including the INVINCIBLE-4 study in early-stage operable triple negative breast cancer and the INVINCIBLE-3 study in selected soft tissue sarcoma subtypes. Updates also address financial results, cash resources, intellectual-property protection for the intratumoral technology platform, at-the-market financing activity, Nasdaq listing compliance, and capital-structure actions affecting the company’s common stock.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Intensity Therapeutics presented promising results from the INVINCIBLE study at the San Antonio Breast Cancer Symposium. In this Phase 2 trial, the drug INT230-6 achieved up to 100% tumor necrosis in patients with early-stage breast cancer, demonstrating significant immune response activation. The study involved 91 participants and highlighted INT230-6's potential as a pre-surgical treatment with manageable adverse effects. The data is bound to impact future cancer therapy approaches and reinforces the company's pioneering position in immune-based cancer treatments.